◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Colgate-Palmolive (India) Limited (COLPAL) Revenue 2023–2026

Name: Colgate-Palmolive (India) Limited (COLPAL) revenue history 2023-2026
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-20

Colgate-Palmolive (India) Limited annual revenue for fiscal 2026 was ₹59.8 billion, a decrease of 0.3% from ₹60.0 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

COLPAL Annual Revenue

Revenue (annual)	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Total Revenue	₹59.8B	₹60.0B	₹56.4B	₹51.9B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

COLPAL Quarterly Revenue

Revenue (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-06-30	2025-03-31	2024-12-31
Total Revenue	₹15.9B	₹15.8B	₹14.7B	₹14.2B	₹14.5B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Revenue at Comparable Companies

MARICO Revenue — Marico Limited
GODREJCP Revenue — Godrej Consumer Products Limited
DABUR Revenue — Dabur India Limited
4527 Revenue — Rohto Pharmaceutical Co.,Ltd.
4912 Revenue — Lion Corporation
4967 Revenue — Kobayashi Pharmaceutical Co., Ltd.

More COLPAL metrics: Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow

All COLPAL financial statements → Interactive COLPAL charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.